The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Risankizumab Advanced Therapy in Crohn's Disease

Effective mucosal healing in Crohn's via IL-23 blockade.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Dahiliye (İç Hastalıkları) department. Book Appointment →

What is Risankizumab Advanced Therapy in Crohn's Disease?

Risankizumab is a targeted monoclonal antibody that suppresses the Th17/Th22 pathway by blocking the p19 subunit of IL-23. It is an effective and safe option in moderate-to-severe Crohn's disease.

ADVANCE, MOTIVATE, and FORTIFY trials demonstrated significant efficacy in endoscopic and clinical response during induction and maintenance therapy. The long-term safety profile is favorable.

It is a promising new option particularly in patients unresponsive to anti-TNF or ustekinumab and in biologic-experienced patients. Subcutaneous maintenance enhances patient adherence.

Symptoms

Abdominal pain and diarrhea
Weight loss and growth retardation
Anal fistulas and abscesses
Perianal pain
Bloody stools
Joint pain
Fatigue and anemia

Risk Factors

Anti-TNF failure
Loss of response to ustekinumab
Complicated fistulizing disease
Aggressive course at young age
Smoking
High CRP and fecal calprotectin
Deep mucosal damage

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Active Crohn's unresponsive to biologic therapy
  • Search for new therapy after relapse
  • Progression of fistulizing disease
  • Lack of endoscopic healing
  • Increase in extraintestinal findings
  • Decision to try a new biologic

Treatment Methods

01
Risankizumab IV induction
02
Subcutaneous maintenance dose
03
Therapeutic drug level monitoring
04
Combination therapy (steroid tapering)
05
Endoscopic and MR enterography monitoring
06
Multidisciplinary approach in perianal disease
07
Infection and tumor screening
08
Long-term safety monitoring

Which Department to Visit?

You can visit our Dahiliye (İç Hastalıkları) department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Dahiliye (İç Hastalıkları) Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.